21:20 , Nov 9, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer; cancer In vitro , cell culture and mouse studies identified a CDK9 inhibitor that could help treat colorectal and other cancers. Screening of a natural product library followed by chemical synthesis and...
15:29 , Nov 8, 2018 |  BC Innovations  |  Translation in Brief

Solid plans for CDK9

A team led by Temple University scientists has shed light on a new epigenetic mechanism behind a known cancer target, cyclin dependent kinase 9 (CDK9), that may broaden the scope of CDK9 inhibitors to include...
23:10 , Mar 20, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer; autoimmune disease

INDICATION: Solid tumors; Crohn’s disease; inflammatory bowel disease (IBD) In vitro , cell culture and mouse studies suggest inhibiting CDK9 and GSK3 could help treat cancer, Crohn’s disease and ulcerative colitis. Chemical synthesis and in...
23:08 , Mar 20, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Prostate cancer Cell culture studies suggest inhibiting CDK9 could help treat castration-resistant prostate cancer (CRPC) that is resistant to BET bromodomain protein inhibitors. In a human BET inhibitor-resistant CRPC cell line, siRNA targeting CDK9...
16:06 , Jun 27, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Epithelial cancer; leukemia; lymphoma In vitro and cell culture studies suggest inhibiting hyperphosphorylation of BRD4 could help treat NUT midline carcinoma (NMC) and other cancers. In human NMC, leukemia and lymphoma cell lines, levels...
21:08 , Dec 30, 2016 |  BC Week In Review  |  Company News

Sumitomo, Tolero deal

Sumitomo will acquire Tolero for $200 million up front, up to $430 million in development milestones and up to $150 million in sales milestones. The deal will provide Sumitomo with alvocidib flavopiridol, which has completed...
00:11 , Dec 22, 2016 |  BC Extra  |  Company News

Sumitomo acquiring Tolero

Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) will acquire oncology and hematology company Tolero Pharmaceuticals Inc. (Lehi, Utah) for $200 million up front plus milestones. The deal provides Sumitomo with alvocidib (formerly HMR 1275 ), a...
07:00 , Sep 29, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Caspase-3 (CASP3; CPP32); cyclin dependent kinase (CDK)

Infectious disease INDICATION: Viral infection Cell culture studies suggest the pan-caspase inhibitor emricasan, the generic antihelminthic niclosamide or CDK inhibitors could help treat Zika. In a Zika virus-infected human glioblastoma cell line, screening of 6,000...
08:00 , Dec 14, 2015 |  BioCentury  |  Product Development

Following CoMMpass

Amidst a flood of promising data for hot targets, indications and technologies at this year's American Society of Hematology meeting, one collection of presentations stands out not only for the wide-reaching implications of their data,...
08:00 , Nov 23, 2015 |  BC Week In Review  |  Company News

Eutropics, Tolero Pharmaceuticals deal

Eutropics granted Tolero exclusive rights to use Eutropics’ Praedicare-Dx biomarker platform in the development of Tolero’s alvocidib. The companies partnered in 2014 to use platform to predict responses to Tolero’s compounds to treat hematological malignancies....